Extranodal NK/T-cell lymphoma, nasal type

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Lymphoma, PTCL, Patent, Peripheral T-cell lymphoma, Extranodal NK/T-cell lymphoma, nasal type, Probability, Drug development, Hematology, Creatinine, DLBCL, Crizotinib, Valganciclovir, United States patent law, G&A, CMO, B-cell lymphoma, Stage 2, Transplant, Journal, American Society of Hematology, State, Patient, Investment, Cytopenia, EBV, Bone marrow, T-cell lymphoma, Financial toxicity, R, Research, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patent and Trademark Office, Stomach, Society, Food, Pharmaceutical industry, Vaccine, Platinum, Fine chemical, Leiomyosarcoma, Lymphoepithelioma

“In the second quarter of 2023, we achieved key milestones in the pivotal NAVAL-1 study of Nana-val by enabling the advancement of this global clinical trial into Stage 2 and establishing EBV-positive PTCL as Nana-val’s leading indication.

Key Points: 
  • “In the second quarter of 2023, we achieved key milestones in the pivotal NAVAL-1 study of Nana-val by enabling the advancement of this global clinical trial into Stage 2 and establishing EBV-positive PTCL as Nana-val’s leading indication.
  • Prioritization also enables the allocation of resources to those indications with the greatest probability of success and market opportunity in key geographies.
  • Patients with extranodal NK/T-cell lymphoma (ENKTL) and other ultra-rare subtypes of EBV+ lymphoma will continue to be enrolled.
  • In July 2023, Viracta received a Notice of Allowance from the US Patent and Trademark Office on Viracta’s patent claims directed to a next-generation formulation of nanatinostat.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Call, Total, TCL, PRS, ALC, BioRxiv, RCC, Neoplasm, KCRC, ITK, Lymphoma, Clinical trial, Extranodal NK/T-cell lymphoma, nasal type, Head, ICB, NSCLC, Cell, Lung cancer, Time management, Preprint, Colon, ATM, American Association for Cancer Research, International Conference on Afghanistan, London (2010), Japanese Cancer Association, Patient, Ipilimumab, Melanoma, Blood, Cancer, Kidney cancer, CR, Webcast, Research, FDA, Pembrolizumab, PR, Safety, Nivolumab, Communications satellite, Pharmaceutical industry, Cryptocurrency, Corvus, Conference

BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • Based on its current plans, Corvus expects its cash to fund operations into the second half of 2024.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the second quarter 2023 financial results.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Call, Total, AACR, TCL, PRS, ALC, RCC, Neoplasm, KCRC, ITK, Clinical trial, Extranodal NK/T-cell lymphoma, nasal type, American Association for Cancer Research, Head, T-cell lymphoma, NSCLC, Lung cancer, Immunotherapy, Bone marrow, Hematological Cancer Research Investment and Education Act, Patient, Ipilimumab, BID, Blood, Immune system, Kidney cancer, CR, Growth, Research, FDA, B16, Pembrolizumab, PR, Safety, Nivolumab, Pharmaceutical industry, Cryptocurrency, Corvus, Conference

BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2023.
  • The clinical trial is expected to enroll up to 60 patients and initial data is anticipated before the end of 2023.
  • As of March 31, 2023, Corvus had cash, cash equivalents and marketable securities totaling $34.5 million.
  • The decrease of $0.5 million was primarily due to lower clinical trial and manufacturing costs associated with the development of mupadolimab.

Life Science Tools Global Market Report 2022: Increased Government Funding For Life Science Technologies Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Biotechnology, Health, Science, Other Science, Research, Government, Biomedical Advanced Research and Development Authority, RNA, Infection, NHGRI, Extranodal NK/T-cell lymphoma, nasal type, TCR, AFA, 3D, Research, COVID-19, DNA, USD, Genomics, CAR, Growth, NK, Development, EUA, Cell biology, B cell, D, Investment, FDA, Hospital, National Human Genome Research Institute, Organization, The National, NIH, Eua Sunthornsanan, Workflow, Diagnosis, ID, BARDA, Renewable energy, Fine chemical, Pharmaceutical industry, Proteomics

The global life science tools market size is expected to reach USD 248.05 billion by 2030, expanding at a CAGR of 6.95% from 2022 to 2030.

Key Points: 
  • The global life science tools market size is expected to reach USD 248.05 billion by 2030, expanding at a CAGR of 6.95% from 2022 to 2030.
  • This growth can be attributed to a rise in government funding for life science technologies, demand for cell and gene therapies, an increase in the adoption of biopharmaceuticals, and growing competition among prominent companies in the market.
  • Additionally, the life science tools industry is expanding based on the increasing investments by the government for the advancement of research and technologies.
  • Thus, the increase in government funding for life science research as well as technologies is expected to drive the market in the coming years.

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

Retrieved on: 
Monday, December 12, 2022
Follicular lymphoma, Annual report, Lymphatic system, Security (finance), Webcast, EHA, Phenotype, Tisagenlecleucel, CRS, ASH, Cure, B-ALL, Toxicity, Extranodal NK/T-cell lymphoma, nasal type, IQR, Lymphoma, COVID-19, CD22, Human, Acute leukemia, CAR, CNS, Lymphoid leukemia, Safety, CLL, Cancer, Bone marrow, University College London, B-cell lymphoma, T-cell lymphoma, Risk, MRD, Society, Peripheral T-cell lymphoma, ALL, UCL, Engineering, Doctor of Philosophy, ORR, Rate, NHL, TRBC1, Patient, Investigational New Drug, Cell, SCT, CD19, Toxic shock syndrome, Royal College of Pathologists, Blackstone, MCL, Therapy, Pharmaceutical industry, Vaccine, Medical device, MD, DLBCL

Importantly, we have not observed antigen negative relapse,” said Dr. Martin Pule, Chief Scientific Officer at Autolus.

Key Points: 
  • Importantly, we have not observed antigen negative relapse,” said Dr. Martin Pule, Chief Scientific Officer at Autolus.
  • “In the AUTO4 study, some patients have experienced durable metabolic CRs, including one patient up to the one-year mark.
  • A simultaneous audio webcast and replay will be accessible on the events section of Autolus website.
  • In collaboration with Autolus’ academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL.

Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

Retrieved on: 
Monday, December 5, 2022
Samsung Medical Center, Phase, ESMO, Extranodal NK/T-cell lymphoma, nasal type, Annual report, SAN, Incidence, Immunoglobulin G, Partnership, Security (finance), Antibody, Autoimmune disease, FDA, PHN, Safety, Cancer, Congress, PD-1, Pain, Trial of the century, RTX, Risk, ADCC, Recurrence, Vaccine, European Society for Medical Oncology, Principal, Sciatica, CD47, Osteoarthritis, Toxicity, Oncology, Radiation, TRPV1, FC, Therapy, Postherpetic neuralgia, Patient, PD-L1, Pharmaceutical industry, Generic drug, COVID-19

ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento .

Key Points: 
  • ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento .
  • The Phase II NK/T-cell lymphoma study was selected for an oral presentation at the Asian Congress of the European Society for Medical Oncology (ESMO Asia 2022) in Singapore on December 4th, 2022.
  • Due to the absence of standard-of-care treatment for relapsed/refractory cases, NK/T lymphoma represents a high unmet medical need and significant market opportunity.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.

ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia

Retrieved on: 
Monday, December 5, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Immunoglobulin G, Recurrence, Oncology, European Society for Medical Oncology, Extranodal NK/T-cell lymphoma, nasal type, FC, PD-L1, Patient, CR, Toxicity, Radiation, CD47, PD-1, Samsung Medical Center, Incidence, ESMO, Safety, ADCC, Principal, Congress, Pharmaceutical industry, Vaccine

The clinical data demonstrated that 6 out of 10 evaluable patients (60%) achieved an objective response, all of whom showed a complete remission (CR).

Key Points: 
  • The clinical data demonstrated that 6 out of 10 evaluable patients (60%) achieved an objective response, all of whom showed a complete remission (CR).
  • Thanks to these achievements, the results of IMC-001 were selected for Mini Oral Session at ESMO Asia this year.
  • These results are expected to satisfy the criteria for approval and lead to globalization of an immune checkpoint inhibitor developed by a Korean biotech.
  • IMC-001 is a PD-L1 antibody, an immune checkpoint inhibitor that serves as the basis of the current immuno-oncology market.

EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Review, Forward-looking statement, Marketing, G1 Therapeutics, MHRA, Investment, Food, Nasdaq, Webcast, File, Partnership, Risk, Breakthrough therapy, Technology, FAQ, Extranodal NK/T-cell lymphoma, nasal type, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, R, Cancer, OS, SEC, Annual report, Safety, Lung, Endometrial cancer, Survival, Breast, EMA, Company, D, Standard of care, European Medicines Agency, Patient, Social media, PARP1, NSCLC, MAA, FDA, EGFR, Pharmaceutical industry, Bank, Vaccine, Birth control

ET

Key Points: 
  • ET
    CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients, today provided a business update and reported financial results for the third quarter ended September 30, 2022.
  • As such, EQRx plans to discontinue future U.S. development efforts for sugemalimab plus chemotherapy in this indication.
  • EQRx remains in discussions with the FDA on an approval pathway for extranodal NK/T-cell lymphoma (ENKTL).
  • As a result, EQRx encourages investors, the media and other interested parties to review the information that EQRx posts there on a regular basis.

Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Patient, ORR, Angioimmunoblastic T-cell lymphoma, Company, Progression-free survival, Fatigue, B-cell lymphoma, Therapy, Risk, III/IV, PM, Society, PRS, Peripheral T-cell lymphoma, NDAS, Safety, IND, Time in China, GemOx, ASH, Relapse, SEHK, PFS, Extranodal NK/T-cell lymphoma, nasal type, Nature, CEO, NDA, LAUNCH, CR, Nausea, Greater, Annual report, Hematology, Vomiting, Genta (company), Hong Kong Stock Exchange, ET, ALCL, Natural killer cell, SDS, Time, Phases of clinical research, PTCL-NOS, Fine chemical, Pharmaceutical industry, Dexamethasone

SHANGHAI and HONG KONG, Nov. 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that it will present updated results from the Phase Ib TOUCH study of selinexor for treatment of R/R T and NK-cell lymphoma in a poster at the upcoming 2022 American Society of Hematology (ASH) Annual Meeting. In addition, preliminary results from the investigator-initiated LAUNCH trial will be published in an on-line abstract. The 2022 ASH Annual Meeting will be held virtually and in person in New Orleans, Louisiana, the United States, from December 10-13, 2022.

Key Points: 
  • In addition, preliminary results from the investigator-initiated LAUNCH trial will be published in an on-line abstract.
  • The 2022 ASH Annual Meeting will be held virtually and in person in New Orleans, Louisiana, the United States, from December 10-13, 2022.
  • "The data to be presented at ASH 2022 highlights the broad clinical potential and manageable side effect profile of selinexor in patients with well-defined T-cell lymphomas and R/R MM," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO.
  • "It is our great pleasureto share these updates with the hematology/oncology community at ASH 2022."

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Retrieved on: 
Thursday, November 3, 2022
Company, BTK, Cytokine, ITK, Investment, CD73, Society, T-cell lymphoma, Board, GLOBE, Safety, Biomarker, Neoplasm, NK, Conference, ASH, A2A, Patient, Extranodal NK/T-cell lymphoma, nasal type, Interim, NASDAQ, Allergy, Partnership, Infection, Autoimmunity, Board of directors, Degenerative disease, Exposition, Leukemia, Antigen, Cancer, PK, Immunity, Pharmaceutical industry, Vaccine, Medical device, T helper cell, TH1, Webcast, Corvus

We look forward to presenting new data from our Phase 1/1b trial, which is being conducted in partnership with Angel Pharmaceuticals in China, at the ASH meeting.

Key Points: 
  • We look forward to presenting new data from our Phase 1/1b trial, which is being conducted in partnership with Angel Pharmaceuticals in China, at the ASH meeting.
  • We anticipate the data will provide an update on safety and the activity of the optimal dose of CPI-818 in T cell lymphoma patients.
  • A webcast of the event will be available on the Corvus website at www.corvuspharma.com .
  • Angel Pharmaceuticals licensed the rights to develop and commercialize Corvus three clinical-stage candidates CPI-818, ciforadenant and mupadolimab in greaterChinaand obtained global rights to Corvus BTK inhibitor preclinical programs.